AI Medical Service Appoints Former Executive Vice President of Boston Scientific Japan, Yasushi Takigawa, as New President — Transition to New Joint Management Structure

AI Medical Service Inc. (Headquarters: Toshima-ku, Tokyo; Representative Director: Tomohiro Tada; hereinafter “AIM”), a medical start-up specializing in the development of diagnostic endoscopic AI, is pleased to announce that effective June 1, 2025, Tomohiro Tada has assumed the role of Chairman and Representative Director, and Yasushi Takigawa has been appointed as President and Representative Director. With this transition to a co-representative management structure, AIM aims to further accelerate its business growth under a more robust executive foundation.

■ Background and Purpose of the New Management Structure 

Founded in 2017 by Dr. Tomohiro Tada with a strong desire to solve challenges in endoscopic medicine, AIM has been advancing with the mission of “Save Lives All Over the World.” After approximately seven years of research and development as a deep-tech startup, AIM successfully launched its first AI-powered endoscopic detection support software (hereinafter “endoscopic AI”) in March 2024. In May 2025, the company released a second-generation endoscopic AI product featuring refinements based on feedback from the clinical environment, furthering the implementation of AI into endoscopic practice.

Japan is currently facing a host of serious structural challenges, including mounting social security costs, a shortage of medical professionals, and the need to reform medical workflows, all driven by a rapidly aging and shrinking population. These changes are placing significant strain on the Japanese medical system, demanding fundamental transformation through innovation.

As AIM shifts from its R&D phase to full-scale commercialization, this new leadership structure will support more agile and long-term decision-making. With the new management team in place, AIM is committed to evolving into a company that delivers sustainable, high-impact solutions to structural issues facing both the medical industry and society at large.

■ Executive Profiles and Comments 

・ Chairman and Representative Director: Tomohiro Tada

【Profile】

Dr Tomohiro TADA is the Chairman  of AI Medical Service Inc., the founder of Tada Tomohiro The Institute of Gastroenterology & Proctology, and Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo Hospital.

Dr TADA received his M.D. from The University of Tokyo School of Medicine in 1996 and Ph.D. in 2005 from The University of Tokyo Graduate School of Medicine, Department of Surgical Sciences. He trained in Colorectal Surgery at The University of Tokyo Hospital.

Clinical Specialty

Gastrointestinal Endoscopy

Board Certifications

Japan Gastroenterological Endoscopy Society, Board Certified Fellow
Japan Society of Gastroenterology
FJGES (Fellow of Japan Gastroenterological Endoscopy Society)
Japanese Gastroenterological Association 

【Comment】

I’m very pleased to welcome Mr. Yasushi Takigawa as our new President and excited to officially make this announcement.

Now that AIM has progressed from R&D to commercialization, I am confident that Mr. Takigawa’s deep expertise in the endoscopy business and his leadership experience at global companies will empower AIM to become a true global niche leader.

Although I have assumed the role of Chairman, I have no intention of stepping away from day-to-day business activities. I will continue to devote my full energy to achieving what only a physician-led company can, by leveraging my medical expertise and past experiences.

AIM remains committed to our mission of “Save Lives All Over the World,” advancing the field of endoscopic medicine, and building a globally competitive medical device industry originating in Japan. We deeply appreciate your continued support and encouragement.

・President and Representative Director: Yasushi Takigawa

【Profile】

Graduated from the College of Economics at Kobe University and earned an MBA from the Graduate School of Management at Clark University in the United States.

Began his career at Sumitomo Bank (now Sumitomo Mitsui Banking Corporation), where he served for 15 years. Later joined JMS Co., Ltd., where he established JMS North America Corporation and was appointed as an Executive Officer at the company’s headquarters.

In 2008, founded the consulting firm Wedge Partners LLC. In 2009, led the commercialization of kidney disease diagnostic biomarkers at CMIC Co., Ltd.

In 2011, co-founded Otsuka Medical Devices Co., Ltd. and served as Executive Vice President.

Joined Boston Scientific Japan K.K. in 2015, where he oversaw Business Development in the endoscopy and CRM divisions, eventually serving as Executive Vice President and Head of Business Development for the Asia-Pacific region.

Appointed President and Representative Director of Genesis MedTech Japan K.K. in 2022.

In 2024, became a Partner in charge of the healthcare sector at RBG Partners, Inc.

【Comment】

I am honored to join AI Medical Service as President under the new management structure.

As demand for healthcare services rapidly increases, those of us in the industry must meet public expectations for quality and access while also improving user experience and reducing costs. 

Given these circumstances, the convergence of AI and healthcare is driving profound change in the medical field.

Since its founding, AIM has boldly pursued the mission of “Save Lives All Over the World.” As we enter what I would call a ‘second founding phase,’ I am committed to building on AIM’s values while leading the company into its next stage of growth and transformation.

Together with all our stakeholders, I will work to unlock AIM’s full potential. I sincerely appreciate your continued support and guidance.